Personalisierte Medizin bei der rheumatoiden Arthritis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Zeitschrift für Rheumatologie (Print)

• Publication date

  2012-12-07

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00393-011-0885-4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

  2012cited by this paper
• 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

  2012cited by this paper
• A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.

  2012cited by this paper
• Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin.

  2012cited by this paper
• Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

  2011cited by this paper
• Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

  2011cited by this paper
• Baseline Numbers of Circulating CD28-negative T Cells May Predict Clinical Response to Abatacept in Patients with Rheumatoid Arthritis

  2011cited by this paper
• Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration

  2011cited by this paper
• A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis

  2011cited by this paper
• B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.

  2011cited by this paper
• Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative

  2010cited by this paper
• Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

  2010cited by this paper
• Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

  2010cited by this paper
• Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

  2010cited by this paper
• 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

  2010cited by this paper
• Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.

  2009cited by this paper
• Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.

  2009cited by this paper
• Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies

  2008cited by this paper
• Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study

  2008cited by this paper
• Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

  2008cited by this paper
• Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.

  2008cited by this paper
• Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

  2007cited by this paper
• Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.

  2007cited by this paper
• Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort

  2007cited by this paper
• The effects of rituximab treatment during pregnancy on a neonate.

  2006cited by this paper
• Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis

  2006cited by this paper
• The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

  2006cited by this paper
• Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

  2006cited by this paper
• Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis.

  2006cited by this paper
• Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

  2006cited by this paper
• Selective Costimulation Modulators: A Novel Approach for the Treatment of Rheumatoid Arthritis

  2005cited by this paper
• Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

  2005cited by this paper
• Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis.

  2004cited by this paper
• Safety of rituximab therapy during the first trimester of pregnancy: a case history

  2004cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA 4 Ig

  2003cited by this paper
• Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

  2003cited by this paper
• Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial.

  2002cited by this paper
• Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.

  2001cited by this paper
• Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

  2001cited by this paper
• CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.

  1996cited by this paper
• Biologics: Targets and Therapy

  year unknowncited by this paper

• No citing papers are available for this paper.